Can I Take Turmeric or Curcumin with Nurtec ODT (Rimegepant)?

What Is Rimegepant and Why Do Women Use It?

Rimegepant (Nurtec ODT) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in February 2020 for acute treatment of migraine and in May 2021 for episodic migraine prevention in adults. Migraine affects roughly three times as many women as men, and hormonal fluctuations across the menstrual cycle, perimenopause, and the postpartum period all drive that disparity.

How Rimegepant Works

CGRP is a neuropeptide released during migraine attacks. It dilates cranial blood vessels and amplifies pain signaling in the trigeminal nerve. Rimegepant blocks the CGRP receptor without causing vasoconstriction, which is why it is safe for women with cardiovascular risk factors or a history of medication-overuse headache.

Why Women at Different Life Stages Reach for It

• Reproductive years. Menstrual migraine, defined as attacks consistently occurring within two days before to three days after the start of menstruation, affects approximately 35 to 51 percent of women with migraine. Rimegepant can be taken preventively on days when migraine is most likely, making it one of the few options designed for short-term, cycle-timed prevention.
• Perimenopause. Estrogen fluctuations intensify in the late reproductive years, and migraine frequency often spikes at this time. Women seeking non-hormonal migraine relief commonly land on CGRP-pathway drugs.
• Postpartum and lactation. Triptans and some older preventives carry warnings or unclear data. The CGRP class is newer, and the lactation data is thin (see the pregnancy and lactation section below).

Why Women Take Turmeric or Curcumin at the Same Time

Turmeric (Curcuma longa) root and its active polyphenol, curcumin, sit among the five most purchased dietary supplements in the United States. Women reach for them primarily for joint and muscle inflammation, gut symptoms, and general anti-inflammatory support. Because migraine itself involves neuroinflammation, some women take curcumin specifically hoping it will reduce headache frequency.

Curcumin has demonstrated anti-inflammatory activity in several randomized controlled trials. A 2021 systematic review in Phytotherapy Research found that curcumin supplementation significantly reduced C-reactive protein and interleukin-6, both markers of inflammation. Whether that translates into meaningful migraine prevention has not been tested in a large RCT as of early 2025.

The overlap is real: a woman managing hormonal migraine preventively with every-other-day rimegepant who is also taking a curcumin complex for joint pain or PCOS-related inflammation is not a rare clinical scenario.

The Pharmacokinetic Interaction: CYP3A4 and P-Glycoprotein

This is where the most clinically meaningful concern lives.

How Rimegepant Is Metabolized

Rimegepant is metabolized primarily by CYP3A4 and, to a lesser degree, CYP2C9. It is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). The FDA prescribing information for Nurtec ODT explicitly warns against co-administration with strong or moderate CYP3A4 inhibitors, because those drugs can raise rimegepant plasma exposure meaningfully, and against strong P-gp or BCRP inhibitors for the same reason.

What Curcumin Does to Those Pathways

Curcumin inhibits CYP3A4 and P-gp in vitro. Multiple in vitro studies have documented curcumin-mediated CYP3A4 inhibition, and curcumin has been shown to inhibit P-gp efflux in cell models. The critical question is whether the doses women actually take produce meaningful inhibition in living tissue, and that is where the data thins out.

The Translation Problem: In Vitro Versus In Vivo

Curcumin is poorly absorbed orally. Bioavailability of unformulated curcumin is estimated at less than 1 percent due to rapid metabolism and poor solubilization. Most commercial supplements now use enhanced-bioavailability formulations: piperine combinations, phytosomes, liposomal encapsulation, or nanoparticle systems. These can increase curcumin plasma levels by 20-fold or more compared to standard powder.

This matters directly for the interaction calculation. A woman taking 500 mg of standard turmeric powder likely achieves curcumin plasma concentrations too low to inhibit hepatic CYP3A4 appreciably. A woman taking a high-bioavailability curcumin phytosome at 1,000 to 1,500 mg daily is in different territory, even if no dedicated rimegepant-curcumin pharmacokinetic study yet exists to quantify the effect size.

WomanRx Interaction Risk Tier for Curcumin + Rimegepant, by Curcumin Formulation:

| Curcumin Formulation | Typical Oral Dose | Estimated CYP3A4 Inhibition Risk | WomanRx Guidance | |---|---|---|---| | Standard turmeric powder (2-5% curcumin) | 500-1,000 mg/day | Low | Generally safe; inform clinician | | Curcumin + piperine (BioPerine) | 500-1,000 mg curcumin | Low to moderate | Monitor; avoid high-end doses | | Curcumin phytosome (Meriva) | 500-1,500 mg/day | Moderate | Discuss with prescriber before combining | | Liposomal or nanoparticle curcumin | 200-600 mg/day | Moderate | Discuss with prescriber before combining |

This framework is based on curcumin pharmacokinetic data and rimegepant metabolic pathway data; no direct head-to-head pharmacokinetic trial has been conducted in humans.

The Pharmacodynamic Interaction: Antiplatelet and Bleeding Risk

Beyond metabolism, there is a second layer: both rimegepant and curcumin have antiplatelet activity, though through different mechanisms.

Curcumin's Antiplatelet Mechanism

Curcumin inhibits thromboxane B2 synthesis and platelet aggregation in ex vivo studies, acting on arachidonic acid pathways in a manner somewhat similar to aspirin. At high doses (roughly >1 g curcumin per day), this becomes measurable, particularly in women who also take NSAIDs, aspirin, or other antiplatelet agents.

Rimegepant's Antiplatelet Role

Rimegepant's primary mechanism is CGRP receptor blockade, not platelet inhibition. However, CGRP itself has vasodilatory and some pro-platelet effects, and blocking the receptor may marginally shift the hemostatic balance. This is theoretical, and the clinical significance in otherwise-healthy women is not established.

Who This Matters Most For

Women with inherited clotting disorders like factor V Leiden (which paradoxically can increase clot risk), women on anticoagulation for atrial fibrillation or a history of venous thromboembolism, or women in the perimenopause who are taking low-dose aspirin for cardiovascular prevention should flag this combination to their prescriber. For a healthy woman in her 30s taking occasional curcumin, the antiplatelet overlap is unlikely to cause harm.

Pregnancy and Lactation: What Every Woman Needs to Know

Rimegepant in pregnancy: avoid it. The FDA prescribing label for Nurtec ODT states that available data are insufficient to determine a drug-associated risk of major birth defects or miscarriage. Animal reproductive studies showed adverse effects on fetal weight and development at doses that produced maternal plasma exposures lower than the human therapeutic exposure. Women who are pregnant or planning pregnancy should not use rimegepant, and an alternative migraine management plan should be in place before conception.

Contraception requirement. Because the reproductive safety data is insufficient, women of reproductive potential should use reliable contraception while taking rimegepant for prevention (every-other-day dosing). Discuss this explicitly with your prescriber, particularly if you are using hormonal contraception, because some combined oral contraceptives are mild CYP3A4 inhibitors and may marginally raise rimegepant exposure.

Rimegepant in lactation: data is very limited. The FDA label notes that rimegepant is present in the milk of lactating animals. No adequate human lactation studies exist. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need. LactMed (the NIH lactation database) currently lists rimegepant as having insufficient data to assess infant risk. If migraine control during lactation is critical, discuss whether a triptan (some of which have more established lactation data) is preferable for acute attacks.

Turmeric in pregnancy and lactation: Culinary amounts of turmeric are generally considered safe in pregnancy. High-dose curcumin supplements are not recommended in pregnancy; curcumin has uterine-stimulating activity in animal models. ACOG does not endorse high-dose herbal supplement use in pregnancy without direct clinical supervision. No formal lactation contraindication exists for culinary turmeric, but high-dose curcumin supplement safety in breastfeeding has not been evaluated in human studies.

Who This Combination Is and Is Not Right For

Women for Whom the Combination Is Likely Low Risk

• Women in their reproductive years taking standard-dose turmeric powder (not high-bioavailability formulations) for general anti-inflammatory support.
• Women using rimegepant only for acute migraine treatment (not every-other-day prevention), because the exposure duration is shorter.
• Women with no bleeding tendency, no anticoagulation, and no concurrent NSAID use.

Women Who Should Have a Prescriber Conversation First

• Women on every-other-day rimegepant prevention taking a high-bioavailability curcumin product at doses above 500 mg curcumin daily.
• Women with PCOS using high-dose curcumin for insulin resistance or inflammation alongside rimegepant, because PCOS frequently co-occurs with migraine.
• Perimenopausal women who have added curcumin for hot flash support and are simultaneously managing worsening migraine with rimegepant.
• Women on concurrent hormonal contraception, hormone therapy, or any anticoagulant.

Women Who Should Not Combine Them Without Direct Supervision

• Women planning pregnancy or confirmed pregnant. Both agents carry reproductive cautions and neither should be escalated in this window.
• Women with known coagulation disorders, platelet dysfunction, or who are scheduled for surgery within two weeks.

Menstrual Migraine and PCOS: Two Conditions Where This Overlap Is Common

Menstrual Migraine

Estrogen withdrawal in the perimenstrual window is the single strongest hormonal trigger for migraine. The International Headache Society criteria for menstrually related migraine require attacks occurring on day -2 through +3 of at least two of three cycles. Rimegepant is increasingly used as a short-term preventive during this window.

Separately, women with menstrual migraine often search for anti-inflammatory supplements to reduce the prostaglandin-mediated cramps and systemic inflammation of menstruation. Curcumin is a common find. The result is a woman taking rimegepant on days -1 through +2 of her cycle while also taking a daily curcumin supplement, which is exactly the scenario this article addresses. The antiplatelet overlap is mildly more relevant during heavy menstrual flow.

PCOS

PCOS affects 6 to 15 percent of reproductive-age women depending on diagnostic criteria and involves chronic low-grade inflammation. Curcumin is actively studied in PCOS for its effect on insulin sensitivity and androgen levels. A 2020 RCT in women with PCOS found that 1,500 mg/day curcumin for 12 weeks significantly reduced fasting insulin and free testosterone. Women with PCOS also have a higher prevalence of migraine. A woman managing both conditions with curcumin and rimegepant should disclose both to a single clinician who can view the full picture.

Perimenopause: The Window Where Both Are Most Commonly Used Together

Perimenopause typically spans four to ten years before the final menstrual period, and estrogen variability during this time is erratic rather than the steady decline that follows menopause. Migraine frequency peaks for many women in early perimenopause, and CGRP-pathway agents are among the recommended non-hormonal options.

At the same time, perimenopausal women frequently add anti-inflammatory supplements hoping to address joint pain, mood, and cardiovascular risk. Curcumin's modest evidence base for inflammation makes it a common pick.

The perimenopausal woman is also more likely to be on concurrent medications: low-dose aspirin for cardiovascular prevention, selective serotonin reuptake inhibitors for mood, or even low-dose hormone therapy. Each of these introduces additional interaction context. The Menopause Society 2023 position statement on non-hormonal therapies does not list curcumin as a recommended non-hormonal treatment for vasomotor symptoms, but it notes the emerging evidence field for complementary approaches.

What to Do If You Are Already Taking Both

You do not need to stop either agent immediately. Follow these steps:

1. Tell your prescriber. List the exact curcumin product, the dose in milligrams of actual curcumin (not turmeric root powder weight), and the formulation type. Bring the bottle.
2. Check your curcumin dose. If you are taking more than 500 mg of curcumin from a high-bioavailability product, consider whether the dose can be reduced or whether a standard turmeric powder form is adequate for your goal.
3. Watch for signals. Unexpected bruising, heavier-than-normal menstrual flow, or a change in how well rimegepant controls your migraines are worth reporting. A change in migraine control could mean altered rimegepant exposure.
4. Timing does not resolve this interaction. Unlike some interactions where separating doses by two hours matters, the CYP3A4 inhibition from curcumin is not meaningfully reversed by dose timing because it affects enzyme activity, not absorption competition. Do not rely on taking the two agents hours apart as a safety strategy.
5. Reassess at your next visit. If you are on preventive rimegepant (every-other-day dosing), your clinician should know your full supplement list at each review.

A Note on Evidence Gaps and What Is Being Extrapolated Here

Women have historically been under-represented in pharmacokinetic drug-drug interaction trials, and supplement-drug interaction research is even thinner. No published clinical pharmacokinetic study has directly measured the effect of curcumin on rimegepant plasma levels in human subjects as of early 2025. The interaction concern articulated in this article is based on:

• Rimegepant's established CYP3A4 and P-gp substrate status (documented in the FDA label and primary PK literature).
• In vitro and limited in vivo evidence that curcumin inhibits CYP3A4 and P-gp.
• The known bioavailability differences across curcumin formulations.
• General pharmacological principles applied to overlapping mechanisms.

This means the risk level is extrapolated, not directly measured. The absence of a documented case report of harm does not equal proven safety. Until a formal drug-supplement interaction study is published, treating this as a low-to-moderate theoretical concern, disclosing it to your clinician, and avoiding unnecessarily high curcumin doses alongside preventive rimegepant is the most defensible position.